Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Naveen Pemmaraju, Luan Hai Phan, Geoffrey Fell, Marlise R. Luskin, Mahesh Swaminathan, Courtney Denton Dinardo, Marina Y Konopleva, Andrew A. Lane
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel
10.1097/hs9.0000000000000841 · 2023
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
10.3324/haematol.2012.072645 · 2013
Epidemiology and survival outcomes in blastic plasmacytoid dendritic cell neoplasm (BPDCN): a US population-based study
10.1182/blood-2023-191150 · 2023
Therapeutic approaches for blastic plasmacytoid dendritic cell neoplasm: allogeneic hematopoietic cell transplantation and novel therapies
10.2991/chi.d.190218.001 · 2019
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients
10.1182/bloodadvances.2020002474 · 2020
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
10.1182/bloodadvances.2023011308 · 2023
Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023
2023
Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm
10.1056/nejmoa1815105 · 2019
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial
10.1001/jamaoncol.2021.1649 · 2021
Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
10.1158/2159-8290.cd-16-0313 · 2016
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020
Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax
10.1158/2159-8290.cd-16-0999 · 2017
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
10.1002/ajh.25000 · 2018
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm
10.1002/ajh.26417 · 2022
More on blastic plasmacytoid dendritic-cell neoplasms
10.1056/nejmc1814963 · 2019
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
10.1182/bloodadvances.2022007879 · 2023
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on standards of care and areas of need
10.1182/blood.2022017865 · 2023
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
10.1038/s41375-023-01968-z · 2023
Diagnosing and treating blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting
2024
Unmet clinical needs and management recommendations for blastic plasmacytoid dendritic cell neoplasm: a consensus-based position paper from an ad hoc international expert panel
10.1097/hs9.0000000000000841 · 2023
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival
10.1182/bloodadvances.2024012797 · 2024
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target
10.3324/haematol.2018.202093 · 2019
Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine
10.1111/ejh.12294 · 2014
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
10.1172/jci128571 · 2019
No additional external references are available.